The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | GLIMMER-01: E-602, a first-in-class bi-sialidase, in solid tumors
Jason Luke, MD, FACP, University of Pittsburgh Medical Center, Pittsburgh, PA, provides an overview of the Phase I/II GLIMMER-01 (NCT05259696) trial of E-602 in solid tumors. E-602 is composed of two engineered human sialidase molecules fused to a human monoclonal antibody. Preclinical studies have demonstrated that E-602 degrades terminal sialic acids on immunosuppressive sialoglycans on both tumor cells and immune cells, restoring both innate and adaptive antitumor immunity. The Phase I portion of the study consists of dose escalation cohorts of E-602 as a monotherapy and in combination with cemiplimab and includes subjects with melanoma, ovarian cancer, non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, breast cancer, gastric/esophagogastric junction (EGJ) cancer, head and neck cancer, or urothelial cancer. The primary endpoints are dose limiting toxicities and safety. Key secondary endpoints include objective response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall-survival (OS). This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
